Diseases & Conditions
Grants & Contracts
News & Events
See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
The primary objective of this NIAID study is to further characterize the natural history of idiopathic CD4 lymphocytopenia (ICL).
A study to learn how coronavirus affects different organs of the body and the function of the body's immune system.
This NIAID research study focuses on an experimental drug which may help treat COVID-19 by supporting the immune system.
A study about how SARS-CoV-2, the virus that causes COVID-19, affects the body, specifically how it affects blood cells and the immune system.
A study about long-term medical problems experienced by people who recover from COVID-19 and whether people who recover develop long-term immunity to SARS-CoV-2, the virus that causes COVID-19.
This study is trying to see whether taking an HCV treatment with fewer clinic visits and laboratory tests can cure just as many people as the standard approach that uses more visits and laboratory tests.
A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS 5423 and GS 2872 in Combination with Capsid Inhibitor Lenacapavir (GS 6207) in Virologically Suppressed Adults with HIV-1 Infection.
People infected with HIV take drugs called antiretrovirals to keep the amount of HIV in their bodies low as well as anticoagulants to treat or prevent blood clots. This study will help gain a better understanding of how antiretrovirals and oral anticoagulants interact with each other.
We want to find out if there are any problems with how HIV-infected children grow and develop as adults, particularly with regard to cardiovascular health.
People infected with HIV are at risk for cardiovascular disease (CVD). This study will evaluate the use of pitavastatin to reduce the risk of CVD in adults infected with HIV who are on antiretroviral therapy (ART).
A small group of people who are HIV positive remain healthy for long periods of time without medications. These Long-Term Non-Progressors have properties within their immune systems that control the virus and can help researchers determine how their immune systems control HIV disease.
This study will look for the development of IRIS (Immune Reconstitution Inflammatory Syndrome), a condition that can happen in patients who are infected with HIV, after they begin treatment with antiretroviral therapy (ART).
The NIH is conducting a research study for people living with HIV and on HIV medications whose CD4 t-cell count is >100 but <350, with an undetectable HIV viral load.
This study will evaluate the preventive vaccine efficacy, safety, and tolerability of the ALVAC-HIV vaccine + Bivalent Subtype C gp120 protein adjuvanted with MF59 in HIV-seronegative South African adults over 24 months from enrollment.
We plan to test the once weekly TB treatment together with different anti-HIV drugs in HIV-negative healthy people. We will study these combinations in up to three different groups of study participants.
Determining how the immune system of some patients is able to control HIV is felt to be a very important step for designing vaccines and therapies for HIV.
This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
The purpose of the study is to test HIV vaccines to see if they are safe. It is not possible to get HIV through participating in the study. Vaccines are used to create resistance to a disease, or to prevent infection. The study vaccines will use a live adenovirus, the type of virus that typically causes cold symptoms. We hope that this adenovirus will help to stimulate an immune response against HIV.
In this study, we will look at whether rifapentine and isoniazid affect blood levels of a commonly used antiretroviral called tenofovir alafenamide, or TAF. The United States Food and Drug Administration (FDA) has approved rifapentine and isoniazid for treating TB.
We are studying the effects of GARDASIL 9 vaccination in people with ICL, which stands for idiopathic CD4 T cell lymphocytopenia. People with ICL get more human papillomavirus (HPV)-related diseases than people without ICL. HPV-related diseases include skin and genital warts and a variety of genital and anal precancerous lesions and cancers. These diseases are also more severe and harder to treat in people with ICL.
We are studying a condition called paradoxical reaction that some people get when they take treatment for tuberculosis (TB). Most people with TB feel better after starting treatment. But for some people, the opposite happens. They may feel better at first, but then suddenly get worse. This opposite effect is a paradoxical reaction. We do not understand how this reaction happens. It can be hard to tell whether worsening symptoms are caused by a paradoxical reaction or something else, such as if the treatment just is not working.
We are asking you to join this study because you have had multiple outbreaks of warts and/or lesions caused by human papillomavirus (HPV). Medicine and surgery are not always effective to treat these outbreaks. We want to follow your HPV outbreaks over a long period of time to better understand how HPV infects the body and causes disease.